to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10562287	
	Filing Date		2005-12-22	
	First Named Inventor Ivon F		F. HELWEGEN, ET AL	
	Art Unit		2656	
	Examiner Name			
	Attorney Docket Numb	er	FR030071	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Pat of cited Doc	lentee or Applicant ument	Releva	,Columns ant Passa; s Appear		
	1	4722079		1988-06-26	MATSUMOTO					
	2	3876842		1975-04-08	BOUWHIS					
	3	4571716		1986-02-18	SZERLIP					
If you wis	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add		
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove		
Examiner	Cite			entee or Applicant		Columns				
Initial*	No	Publication Number	Code <sup>1</sup>	Date				nt Passa s Appear	ges or Ke	levant
Initial*	No 1	Publication Number	Code <sup>1</sup>	Date					ges or Ke	levant
	1	Publication Number			of cited Doc	ument	Figure	s Appear	ges or Ke	levant
	1		shed Ap	plication cita	of cited Doc	ument please click the Ad	Figure	s Appear		levant
	1 h to ac		shed Ap	plication cita	of cited Documents on information	ument please click the Ad	Figure	s Appear	lumns,Lir levant or Releva	es Tr

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10562287		
iling Date		2005-12-22		
irst Named Inventor Ivon F		. HELWEGEN, ET AL		
rt Unit		2656		
xaminer Name				
ttorney Docket Numb	er	FR030071		

1090 OF 30 MATRICUITA IND CO.

	_							-	
	3	62031033	JP	A	1987-02-10	NEC ELEC LTD			
	4	03012829	JP	A	1991-01-21	NHK SPRING CO LTD			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.									
1 ISR Publication. International Publication Number WC2004/114287/A1)									

EXAMINER SIGNATURE

Examiner Signature

Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at your (LSPTO\_GOL) or MPEP 90.04. Esters do the that issued the document, by the two-left code (WIPO\_Soundard ST3.). "For Explaneme patent for comment, the includation of the year of the register of the Empiror many precise the serial results of the patent document."

\*Incl of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST3.16 if possible. \*Deplicant is to place a check mark here if Engine Insurages the resistance is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562287		
Filing Date		2005-12-22		
First Named Inventor Ivon F		HELWEGEN, ET AL		
Art Unit		2656		
Examiner Name				
Attorney Docket Numb	er	FR030071		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appropriate selection(s):
---------------	----------	-------------	------------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-05-18
Name/Print	Michael E. Belk	Registration Number	33,357

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatert and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.